855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE | Publicación